Drug intelligence / Profile preview

KQB548

Development stage: Phase 1
Lead developer: Bayer
Modality: Covalent Small Molecules → Small Molecules

Overview

KQB548 is a small molecule drug candidate developed by Kumquat Biosciences targeting KRAS mutant cancers. It is part of Kumquat's pipeline focused on the RAS pathway, specifically designed to inhibit mutant forms of KRAS, a well-known oncogenic driver in various solid tumors. The compound leverages covalent chemistry to achieve high potency and selectivity for its target, aiming to overcome resistance mechanisms and provide durable therapeutic effects in cancer treatment. As of June 2025, KQB548 is in the IND-enabling stage of development[1].

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on KQB548.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQB548.

Explore the full profile